Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial Meeting Abstract

cited authors

  • Novak, Zoltan; Gold, Michael; Herrstedt, Jorn; Gill, Sarah; Savarese, Antonella; Diaz, John; Kommoss, Stefan; Cantuaria, Guilherme; Boere, Ingrid; Fleming, Evelyn; Gilbert, Lucy; Pennington, Kathryn; Holloway, Robert; Miller, Eirwen; Miller, Rachel; Powell, Matthew; Dabrowski, Christine; Stevens, Shadi; Mirza, Mansoor Raza; Mccourt, Carolyn

Publication Date

  • November 1, 2023

webpage

published in

category

start page

  • A50

end page

  • A51

volume

  • 33

issue

  • SUPPL_4